Alissa Coyne, OD, MS, FAAO, FASOS: No financial relationships to disclose
Glucagon-like peptide-1 (GLP-1) agonists are a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity. This course offers a comprehensive exploration of the relationship between GLP-1 receptor agonists and ocular health including emerging evidence on their impact on ocular conditions, such as diabetic retinopathy, nonarteritic ischemic optic neuropathy, and glaucoma.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Deepen their knowledge of how GLP-1 agonists work, their pharmacological effects, and their role in managing Type 2 Diabetes Mellitus (T2DM) and other metabolic conditions
Gain insights into the expression of GLP-1 receptors in ocular tissues, the potential protective effects of these agonists on the retina and optic nerve, and possible clinical treatment options in the future
Understand how GLP-1 agonists may influence ocular health, including their potential effects on diabetic retinopathy and other ocular conditions, such as NAION
